Ambit Biosciences publish kinase profiling data on 38 kinase inhibitors

Ambit Biosciences have publised a paper in Nature Biotechnology detailing kinase profiles for 38 well-known kinase inhibitors using Ambit’s high-throughput KINOMEscan™ profiling technology.

IKKbeta kinase inhibition has potential in treatment of HTLV-1 infected patients

Treatment of HTLV-1 inhifected cells with IKKbeta kinase inhibitor BMS-345541 has been shown to induce apoptosis.

Imatinib modulates synovial fibroblasts in arthritis model

Data presented at EULAR shows that PDGFR kinase inhibitors can modulate synovial fibroblast activity in a mouse collagen induced arthritis (CIA) model. Drugs tested included imatinib mesylate (Gleevec) and SU9518

Incytes INCB-18424 shows efficacy in RA

Phase I data presented at EULAR show Incytes JAK 1/2 inhibitor INCB018424 to demonstrate efficacy in rheumatoid arthritis (RA) patients and was safe and well-tolerated at 15 mg BID.
Incyte Press Release

GSK to begin Phase I trials with PI3K inhibitor GSK1059615

GSK are about to initiate a Phase I trial in solid tumors and lymphoma with its new PI3K inhibitor GSK1059615

Anti-fibrotic effect of Imatinib does not appear to affect vasculature

Data presented at EULAR show Imatinib does not inhibit proliferation, migration or tube forming in endothelial cells, a possible concernt in its potential antifibrotic use for the treatment of systemic sclerosis

Vertex present Phase II data on p38 inhibitor VX-702 in RA

Phase II data presented at EULAR show Vertex’s p38 MAP kinase inhibitor VX-702 to demonstrate efficacy in the signs and symptoms of Rheumatoid Arthritis (RA)

Array Biopharma present data on p38 inhibitor ARRY-797 and MEK inhibitor ARRY-162 at EULAR

Array Biopharma will be presenting data on two kinase inhibitors at EULAR:
ARRY-797 – p38alpha inhibitor – Inflammation – Phase I data show the drug to be well tolerated and to inhibit production of PGE2, IL-1 and TNF EULAR Abstract
ARRY-162 – MEK inhibitor – RA – Phase I data show the drug to be well [...]

Ardea present preclinical data on MEK inhibitor RDEA119

Ardea Biosciences are to present data on its MEK inhibitor RDEA119 at the 2008 Annual European Congress of Rheumatology. RDEA119 is in development for arthritis. In vivo data show that it significantly reduces paw swelling in a rat carrageenan-induced paw edema model; reduces ankle swelling AIA rats and reduces arthritic scores in the CIA [...]